CAR inhibitors for the treatment of heart attack

In a translational approach, we want to investigate CAR as a therapeutic target protein and develop CAR inhibitors for the treatment of heart disease. Building on our initial evaluation of different CAR inhibitors, we will focus on the production and validation of a human anti-CAR antibody. We aim to improve cardiomyocyte survival, remodelling processes, and the heart's pumping function. This work includes investigations in the cell culture system, which will then be validated in animal models. We are convinced that CAR is an excellent therapeutic target for heart disease based on (1) the protective effect of CAR deficiency after a heart attack, (2) access to inhibitors and (3) the low level of unwanted side effects when CAR is lacking.